StockMarketWire.com - Neuroscience data analytics company Ixico said it had won a contract from Vaccinex to support the latter's trial of pepinemab, a potential treatment of Alzheimer's disease.

The arrangement would build on the company's existing contract to support Vaccinex's study of pepinemab in a Huntington's disease trial.


At 1:25pm: [LON:IXI] IXICO plc share price was -4.5p at 49p



Story provided by StockMarketWire.com